Journal
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
Volume 30, Issue 3, Pages 303-309Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MNH.0000000000000695
Keywords
amyloid typing; amyloidosis; diagnosis; mass spectrometry; nontissue diagnosis
Categories
Ask authors/readers for more resources
Amyloidoses are rare diseases in which treatment depends on the type of amyloid protein, and delays in diagnosis lead to poor prognosis.
Purpose of review Amyloidoses are a group of rare and heterogeneous diseases in which abnormally folded proteins deposit in tissues and lead to organ damage. A brief review of advances in the diagnosis of extracerebral systemic amyloidoses in the context of recent advances in their clinical management is provided. Recent findings Although steady progress in the treatment of AL and AA has evolved over many years, significant advances in the treatment of ATTR, transthyretin-derived amyloidosis, have been achieved only recently. This coincides with the emergence of nontissue diagnosis of cardiac ATTR in both the hereditary and wild-type settings. The latter is emerging as possibly the most prevalent type of systemic amyloidosis. Available treatments are amyloid protein type dependent and, hence, following amyloid detection, amyloid protein typing is necessary. Although mass spectrometry has emerged as the preferred method of amyloid typing, careful application of immune methods is still clinically useful but caution and experience, as well as awareness of the limitations of each method, are necessary in their interpretation. Despite significant advances in the treatment of the systemic amyloidoses, outcomes remain poor, primarily due to delays in diagnosis. Precise diagnosis of the amyloid protein type is critical for treatment selection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available